Details of Disease

General Information of Disease (ID: DISCDT4E)

• Disease Name: Peripheral T-cell lymphoma
• Synonyms: mature T-cell and natural killer cell lymphoma; NK-T cell lymphoma; peripheral T-cell lymphoma; mature T-cell non-Hodgkin's lymphoma; mature T-cell lymphoma; mature T-cell and NK-cell non-Hodgkin's lymphoma; mature T-cell and NK-cell non-Hodgkin lymphoma; mature T-cell and NK-cell lymphoma; mature T-and NK-cell lymphoma; PTCL
• Disease Class: 2A90: Mature T-cell lymphoma
• Definition: This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive of all hematopoietic neoplasms. Representative disease entities include mycosis fungoides, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, and anaplastic large cell lymphoma.
• Disease Hierarchy:
  DISIGU7Q: Neoplasm of mature T-cells or NK-cells
  DISSXRTQ: T-cell lymphoma
  DISCDT4E: Peripheral T-cell lymphoma
• ICD Code:
  ICD-11: ICD-11: 2A90.C
  ICD-10: ICD-10: C84.4
  ICD-9: ICD-9: 202.7
  Expand ICD-11: '2A90.C
  Expand ICD-10: 'C84.4
  Expand ICD-9: 202.7
• Disease Identifiers:
  MONDO ID: MONDO_0000430
  MESH ID: D016411
  UMLS CUI: C5551485
  MedGen ID: 1790498
  Orphanet ID: 86885
  SNOMED CT ID: 109977009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Pralatrexate	DMAO80I	Approved	Small molecular drug	[1]
Romidepsin	DMT5GNL	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[2]
Fenretinide	DMRD5SP	Phase 3	Small molecular drug	[3]
Zarnestra	DMF30HL	Phase 3	Small molecular drug	[2]
AFM13	DMN45IC	Phase 2	Antibody	[4]
Darinaparsin	DMB4OFL	Phase 2	Small molecular drug	[2]
Folotynpralatrexate	DM7UBLG	Phase 2	NA	[2]
Otlertuzumab	DMAZIND	Phase 2	NA	[2]
PDX-101	DM6OC53	Phase 2	Small molecular drug	[2]
TRBC1	DM1ZK4W	Phase 1/2	CAR T Cell Therapy	[5]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6840).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma